Eiger Bio to Participate in September 2020 Investor Conferences
Citi's 15th Annual
BioPharma Conference. Eiger will participate in two panels:
"COVID-19 Therapeutics" on
Wednesday, September 9, 9:50-10:20 AM ET
"Challenges and Opportunities in Rare Disease Drug Development" on
Wednesday, September 9, 4:15-4:45 PM ET
Baird Global Healthcare Conference2020. Eiger will present a corporate update on Wednesday, September 9, 12:50-1:20 PM ET.
H.C. Wainwright22nd Annual Global Investment Conferencefrom September 14- September 16.
Cantor Global Virtual Healthcare Conference2020. Eiger will present a corporate update on Thursday, September 17, 2:00-2:30 PM ET.
Eiger will host one-on-one meetings at all conferences. Live webcasts of the Citi panels and Baird and Cantor presentations will be available on the
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs, for which no approved therapies exist.
Eiger's lead clinical programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.
Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. FDA PDUFA date is
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-bio-to-participate-in-september-2020-investor-conferences-301121571.html